Should every patient with MDS get iron chelation – probably yes.

NA

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Mediterranean Journal of Hematology and Infectious Diseases
المؤلفون الرئيسيون:	Kanjaksha Ghosh, Emanuele Angelucci, Federica Pilo, Kinjalka Ghosh
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	PAGEPress Publications 2017-09-01
الموضوعات:	Anemia , MDS, Iron Overload , Chelation
الوصول للمادة أونلاين:	http://www.mjhid.org/index.php/mjhid/article/view/3061

مواد مشابهة

MYELODYSPLASTIC SYNDROMES AND IRON CHELATION THERAPY
حسب: Emanuele Angelucci, وآخرون
منشور في: (2017-03-01)

Editorial: MDS: new scientific and clinical developments
حسب: Sabine Blum, وآخرون
منشور في: (2025-02-01)

Comparative Study on Iron Content Detection by Energy Spectral CT and MRI in MDS Patients
حسب: Yao Zhang, وآخرون
منشور في: (2021-03-01)

A Review on Iron Chelators in Treatment of Iron Overload Syndromes
حسب: Naser Mobarra, وآخرون
منشور في: (2016-10-01)

Deferasirox, an oral chelator in the treatment of iron overload
حسب: I. Portioli
منشور في: (2013-05-01)

Comparative study of efficacy of different iron chelating agents in treatment of iron overload in children with Beta Thalassemia Major
حسب: adel abd elhaleim hagag
منشور في: (2014-08-01)

New Perspectives on the Impact of Iron Chelation Therapy on the Gut Microbiome in Thalassemia Patients
حسب: Sara Deumić, وآخرون
منشور في: (2025-02-01)

Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine
حسب: Mohamed Abdel Malik Hassan, وآخرون
منشور في: (2016-05-01)

Impact of Sappan Wood Extract as Iron Chelator Adjuvant on Iron Concentration and Macrophage Polarization in Rat Spleen
حسب: Mohammad Ghozali, وآخرون
منشور في: (2025-07-01)

Knowledge, Attitude, and Practice of Young Paediatricians About Chelation Therapyin Transfusion-Dependent Thalassemia Major Children
حسب: Misbah Fakih, وآخرون
منشور في: (2022-12-01)

Prognostic Factors and Clinical Considerations for Iron Chelation Therapy in Myelodysplastic Syndrome Patients
حسب: Parisi S, وآخرون
منشور في: (2021-12-01)

Markers of Renal Complications in Beta Thalassemia Patients with Iron Overload Receiving Chelation Agent Therapy: A Systematic Review
حسب: Romadhon PZ, وآخرون
منشور في: (2022-11-01)

HEMATOPOIETIC CELL TRANSPLANTATION FOR OLDER PATIENTS WITH MDS
حسب: Mazyar Shadman, وآخرون
منشور في: (2014-09-01)

MDS Matrices with Lightweight Circuits
حسب: Sébastien Duval, وآخرون
منشور في: (2018-06-01)

Alterations in the ribosomal machinery in cancer and hematologic disorders
حسب: Shenoy Niraj, وآخرون
منشور في: (2012-06-01)

Iron Chelation as a Potential Therapeutic Approach in Acute Lung Injury
حسب: Xiyang Zhang, وآخرون
منشور في: (2023-07-01)

Myocardial iron is strongly associated with reproductive function in beta-thalassemic women under chelation therapy
حسب: M. A. Castaldi, وآخرون
منشور في: (2020-02-01)

Current State and Challenges in Development of Targeted Therapies in Myelodysplastic Syndromes (MDS)
حسب: Michele Stanchina, وآخرون
منشور في: (2021-04-01)

Iron Overload and Breast Cancer: Iron Chelation as a Potential Therapeutic Approach
حسب: Sufia Islam, وآخرون
منشور في: (2022-06-01)

TRANSIENT ELASTOGRAPHY (TE) IS A USEFUL TOOL FOR ASSESSING THE RESPONSE OF LIVER IRON CHELATION IN SICKLE CELL DISEASE PATIENTS
حسب: SOPHIA DELICOU
منشور في: (2018-09-01)

First Assessment of Oral Iron Chelator HBED Increases Iron Excretion in Black Rhinoceros (<i>Diceros bicornis minor</i>)
حسب: Kathleen E. Sullivan, وآخرون
منشور في: (2025-10-01)

Integrated cytogenetic and genomic profiling of the MDS-L cell line
حسب: Julia Mestre, وآخرون
منشور في: (2025-06-01)

Cardiovascular Complications in β-Thalassemia: Getting to the Heart of It
حسب: Nathalie Akiki, وآخرون
منشور في: (2023-01-01)

The impact of chelation compliance in health outcome and health related quality of life in thalassaemia patients: a systematic review
حسب: Wan Jin Lee, وآخرون
منشور في: (2024-02-01)

Lower‐risk myelodysplastic syndromes: Current treatment options for anemia
حسب: Mathieu Meunier, وآخرون
منشور في: (2022-11-01)

Adherence to Iron Chelation Therapy and Its Determinants
حسب: Sukhmani Sidhu, وآخرون
منشور في: (2021-01-01)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes
حسب: Taher AT, وآخرون
منشور في: (2016-12-01)

Role of iron metabolism genetic determinants in response to chelation therapy in a cohort of β-thalassemia and sickle cell syndromes Italian patients
حسب: Maria Concetta Renda, وآخرون
منشور في: (2014-09-01)

Therapeutic potential of iron chelators in retinal vascular diseases
حسب: Yan Li, وآخرون
منشور في: (2023-11-01)

New Deferric Amine Compounds Efficiently Chelate Excess Iron to Treat Iron Overload Disorders and to Prevent Ferroptosis
حسب: Wenya Feng, وآخرون
منشور في: (2022-10-01)

MDS Code Based Ultralightweight Authentication Protocol for RFID System
حسب: Pramod Kumar Maurya, وآخرون
منشور في: (2023-01-01)

Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study
حسب: Ines Zugasti, وآخرون
منشور في: (2025-04-01)

PROGNOSTIC IMPACT OF IMMUNOHISTOCHEMICAL P53 EXPRESSION IN BONE MARROW BIOPSY IN HIGHER RISK MDS: A PILOT STUDY
حسب: Alfredo Molteni, وآخرون
منشور في: (2019-02-01)

Successful treatment of low‐risk myelodysplastic syndrome‐related anemia in patients with chronic kidney disease with daprodustat: A report of two cases
حسب: Hiroyoshi Kunimoto, وآخرون
منشور في: (2024-12-01)

Beta Thalassemia: An Overview of Epidemiology, Clinical Features, Diagnosis, and Management
حسب: Ghasem Miri-Aliabad
منشور في: (2025-03-01)

Improving MDS Risk Assessment: The Role of Monocytopenia and Lymphocytopenia Beyond IPSS-R
حسب: Marijana Virijevic, وآخرون
منشور في: (2025-09-01)

Predicting MDS-UPDRS-III score changes using mobile device biomarkers
حسب: Semkiv Khrystyna, وآخرون
منشور في: (2024-12-01)

Editorial: Advancing Science for Clinical Care in MDS
حسب: Maria E. Figueroa, وآخرون
منشور في: (2022-04-01)

Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy
حسب: Christoforos K. Vaxevanis, وآخرون
منشور في: (2023-12-01)

Severe iron overload and hyporegenerative anemia in a case with rhesus hemolytic disease: therapeutic approach to rare complications
حسب: Fatih Demircioğlu, وآخرون
منشور في: (2010-09-01)